Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18781928 | CYTOKINE ASSOCIATED TUMOR INFILTRATING LYMPHOCYTES COMPOSITIONS AND METHODS | July 2024 | December 2025 | Abandon | 17 | 2 | 0 | No | Yes |
| 18423752 | ANTIBODIES TO PROGRAMMED CELL DEATH PROTEIN 1 THAT ARE PD-1 AGONISTS | January 2024 | April 2024 | Allow | 3 | 0 | 0 | Yes | No |
| 18405977 | BINDING MOLECULES | January 2024 | August 2024 | Allow | 8 | 0 | 0 | Yes | No |
| 18573191 | THERAPEUTIC TARGETING OF CADHERIN 11 IN CANCER | December 2023 | September 2025 | Allow | 21 | 2 | 0 | Yes | Yes |
| 18041351 | ANTIBODY BINDING TO HUMAN CD38, PREPARATION METHOD THEREOF, AND USE THEREOF | February 2023 | September 2025 | Allow | 31 | 0 | 0 | Yes | No |
| 18077318 | Use of Amivantamab to Treat Colorectal Cancer | December 2022 | April 2025 | Abandon | 28 | 2 | 0 | No | No |
| 18070965 | Combination Of T-Cell Redirecting Multifunctional Antibodies With Immune Checkpoint Modulators And Uses Thereof | November 2022 | November 2025 | Abandon | 36 | 1 | 0 | No | No |
| 17999496 | T CELL RECEPTORS WITH VGLL1 SPECIFICITY AND USES THEREOF | November 2022 | July 2025 | Allow | 32 | 0 | 0 | Yes | No |
| 18051833 | PHARMACEUTICAL COMPOSITION OF A HUMANIZED ANTI-CD40 ANTIBODY | November 2022 | December 2024 | Allow | 26 | 2 | 0 | Yes | No |
| 17922067 | ANTI-CD26 PROTEINS AND USES THEREOF | October 2022 | October 2025 | Allow | 35 | 0 | 1 | Yes | No |
| 17922153 | A NOVEL ANTIBODY BINDING SPECIFICALLY TO HUMAN CEACAM1/3/5 AND USE THEREOF | October 2022 | February 2026 | Abandon | 39 | 1 | 0 | No | No |
| 17811657 | ADOPTIVE T-CELL THERAPY USING EMPD-SPECIFIC CHIMERIC ANTIGEN RECEPTORS FOR TREATING lgE-MEDIATED ALLERGIC DISEASES | July 2022 | December 2025 | Abandon | 41 | 1 | 1 | No | No |
| 17755427 | ANTI-HUMAN CLAUDIN 18.2 ANTIBODY AND APPLICATION THEREOF | April 2022 | January 2026 | Abandon | 45 | 0 | 1 | No | No |
| 17762270 | SINGLE-DOMAIN ANTIBODIES DIRECTED AGAINST LILRB2 | March 2022 | February 2026 | Abandon | 47 | 0 | 1 | No | No |
| 17637686 | METHODS OF TREATING CANCER USING TNFRSF25 ANTIBODIES | February 2022 | September 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17636782 | BCMA ANTIBODY | February 2022 | September 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17631825 | T CELL RECEPTORS AND METHODS OF USE THEREOF | January 2022 | November 2025 | Allow | 45 | 0 | 1 | Yes | No |
| 17574960 | ANTIBODY THAT BINDS TO HUMAN PD-L1 | January 2022 | March 2026 | Abandon | 50 | 2 | 0 | Yes | No |
| 17620264 | ANTI-LRRC25 COMPOSITIONS AND METHODS FOR MODULATING MYELOID CELL INFLAMMATORY PHENOTYPES AND USES THEREOF | December 2021 | October 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17619558 | ANTI-CEA ANTIBODY AND APPLICATION THEREOF | December 2021 | July 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17616103 | ANTI-CANINE PD-1 ANTIBODY BINDING WITH CANINE PD-1 | December 2021 | August 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17615475 | A TETRAVALENT BISPECIFIC ANTIBODY AGAINST PD-1 AND PD-L1 | November 2021 | December 2024 | Allow | 37 | 0 | 0 | Yes | No |
| 17613557 | COMBINATION THERAPIES USING CDK INHIBITORS | November 2021 | September 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17612959 | ANTI-B7-H3 ANTIBODY AND METHODS OF USE THEREOF | November 2021 | June 2025 | Allow | 43 | 1 | 1 | No | No |
| 17519101 | USE OF TUMOR-INDEPENDENT ANTIGENS IN IMMUNOTHERAPIES | November 2021 | November 2025 | Abandon | 48 | 3 | 0 | No | Yes |
| 17503473 | EXTRACELLULAR VESICLE BIOMARKERS FOR ENDOMETRIAL CANCER | October 2021 | January 2025 | Abandon | 39 | 2 | 1 | No | No |
| 17598763 | T CELL RECEPTORS AND METHODS OF USE THEREOF | September 2021 | November 2025 | Allow | 49 | 1 | 1 | Yes | No |
| 17440282 | COMPOSITIONS AND METHODS FOR MODULATING METABOLIC REGULATORS OF T CELL PATHOGENICITY | September 2021 | November 2025 | Abandon | 50 | 1 | 1 | No | No |
| 17447607 | DENDRITIC CELL ASGPR TARGETING IMMUNOTHERAPEUTICS FOR MULTIPLE SCLEROSIS | September 2021 | August 2024 | Allow | 35 | 1 | 1 | Yes | No |
| 17475216 | TRISPECIFIC PROTEINS AND METHODS OF USE | September 2021 | March 2025 | Allow | 42 | 1 | 0 | Yes | No |
| 17436204 | Anti-ICOS Antibodies for the Treatment of Cancer | September 2021 | April 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17429580 | ANTIGEN BINDING MOLECULES AND EPITOPES, AND USES THEREOF | August 2021 | November 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17427882 | ANTI-GITR ANTIGEN-BINDING DOMAINS AND USES THEREOF | August 2021 | May 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17427625 | ANTI-PD-1 ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND PHARMACEUTICAL USE THEREOF | July 2021 | June 2025 | Allow | 46 | 1 | 1 | Yes | No |
| 17386437 | NANOPARTICLE FORMULATIONS | July 2021 | May 2025 | Allow | 46 | 1 | 1 | Yes | No |
| 17424603 | NOVEL CANCER ANTIGENS AND ANTIBODIES OF SAID ANTIGENS | July 2021 | January 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17366545 | Prostate Neoantigens And Their Uses | July 2021 | February 2026 | Allow | 56 | 2 | 1 | Yes | No |
| 17413892 | IMMUNE EFFECTOR CELL TARGETING GPC3 AND APPLICATION THEREOF | June 2021 | February 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17346089 | METHODS OF EXPLOITING ONCOGENIC DRIVERS ALONG THE HUMAN CYCLIN G1 PATHWAY FOR CANCER GENE THERAPY | June 2021 | March 2025 | Abandon | 45 | 1 | 0 | No | No |
| 17343150 | Daratumumab and Hyaluronidase for the Treatment of Multiple Myeloma | June 2021 | May 2025 | Abandon | 47 | 2 | 1 | No | No |
| 17312184 | NOVEL POLYPEPTIDES | June 2021 | February 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17311537 | ENDOTHELIN RECEPTOR TYPE A ACTIVITY REGULATING ANTIBODY | June 2021 | September 2024 | Allow | 40 | 0 | 1 | Yes | No |
| 17290527 | COMPOSITION AND METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES | April 2021 | November 2024 | Abandon | 43 | 0 | 1 | No | No |
| 17290754 | BISPECIFIC ANTIBODY BINDING TO CD20 AND CD3 AND USES THEREOF | April 2021 | April 2025 | Abandon | 48 | 0 | 1 | No | No |
| 17290651 | HOMODIMERIC BISPECIFIC ANTIBODY, PREPARATION METHOD THEREFOR AND USE THEREOF | April 2021 | January 2026 | Abandon | 57 | 0 | 1 | No | No |
| 17288471 | ANTI-HUMAN CD89 ANTIBODIES AND USES THEREOF | April 2021 | September 2024 | Allow | 41 | 1 | 0 | Yes | No |
| 17287756 | IL4/IL13 Receptor Molecule for Veterinary Use | April 2021 | June 2025 | Allow | 49 | 1 | 1 | Yes | No |
| 17283614 | EXOSOME-TARGETING BISPECIFIC ANTIBODIES | April 2021 | October 2024 | Abandon | 42 | 1 | 0 | No | No |
| 17281095 | METHODS FOR EXPANDING T CELLS FOR THE TREATMENT OF CANCER AND RELATED MALIGNANCIES | March 2021 | November 2024 | Abandon | 43 | 1 | 0 | No | No |
| 17275911 | TFR-SPECIFIC BINDING MOIETIES AND TRANSCYTOSIS METHOD TO SELECT VNARS THAT CROSS CELLULAR BARRIERS | March 2021 | March 2025 | Allow | 48 | 1 | 1 | Yes | No |
| 17275233 | MR1 RESTRICTED T CELL RECEPTORS FOR CANCER IMMUNOTHERAPY | March 2021 | March 2025 | Abandon | 48 | 0 | 1 | No | No |
| 17176533 | LEUCINE ZIPPER-BASED COMPOSITIONS AND METHODS OF USE | February 2021 | August 2025 | Allow | 54 | 1 | 1 | Yes | No |
| 17267000 | PROCESSES FOR GENERATING ENGINEERED CELLS AND COMPOSITIONS THEREOF | February 2021 | October 2025 | Allow | 56 | 2 | 1 | Yes | No |
| 17260783 | COMPOSITIONS AND METHODS FOR TREATMENT OF T CELL MALIGNANCIES | January 2021 | December 2024 | Abandon | 47 | 1 | 0 | No | No |
| 17253886 | METHOD FOR THE IN VITRO DIFFERENTIATION AND MATURATION OF DENDRITIC CELLS FOR THERAPEUTIC USE | December 2020 | October 2025 | Allow | 58 | 3 | 1 | Yes | No |
| 17251285 | COMBINATION THERAPY WITH NEOANTIGEN VACCINE | December 2020 | August 2025 | Abandon | 56 | 2 | 1 | No | No |
| 17251118 | STEM CELL-ENGINEERED INKT CELL-BASED OFF-THE-SHELF CELLULAR THERAPY | December 2020 | February 2026 | Abandon | 60 | 2 | 0 | No | Yes |
| 17054483 | METHODS AND COMPOSITIONS FOR TREATING CANCER | November 2020 | October 2024 | Allow | 47 | 2 | 1 | Yes | No |
| 17053925 | BACTERICIDAL/PERMEABILITY INCREASING PROTEIN FOR USE IN A METHOD OF IMMUNIZATION, PREFERABLY AS AN ADJUVANT IN A METHOD OF VACCINATION | November 2020 | September 2025 | Allow | 58 | 3 | 1 | Yes | No |
| 17040472 | CELLULAR IMMUNOTHERAPY COMPOSITIONS AND USES THEREOF | September 2020 | March 2025 | Allow | 54 | 1 | 1 | Yes | No |
| 17015662 | NOVEL ANTI-TROPONIN T ANTIBODIES | September 2020 | November 2024 | Allow | 50 | 1 | 1 | Yes | No |
| 16967881 | Activating Chimeric Receptors and Uses Thereof In Natural Killer Cell Immunotherapy | August 2020 | November 2024 | Allow | 51 | 2 | 0 | Yes | No |
| 16967243 | METHODS FOR TREATING CANCER USING COMBINATIONS OF ANTI-BTNL2 AND IMMUNE CHECKPOINT BLOCKADE AGENTS | August 2020 | February 2025 | Allow | 55 | 1 | 1 | Yes | No |
| 16958250 | METHOD FOR IMPROVING PRODUCTION OF CAR T CELLS | June 2020 | March 2025 | Allow | 57 | 2 | 1 | Yes | No |
| 16642810 | B CELL RECEPTOR MODIFICATION IN B CELLS | February 2020 | October 2024 | Allow | 56 | 3 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CHASE, CAROL ANN.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner CHASE, CAROL ANN works in Art Unit 1646 and has examined 47 patent applications in our dataset. With an allowance rate of 48.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 47 months.
Examiner CHASE, CAROL ANN's allowance rate of 48.9% places them in the 11% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by CHASE, CAROL ANN receive 1.11 office actions before reaching final disposition. This places the examiner in the 12% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by CHASE, CAROL ANN is 47 months. This places the examiner in the 9% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +92.3% benefit to allowance rate for applications examined by CHASE, CAROL ANN. This interview benefit is in the 100% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 43.8% of applications are subsequently allowed. This success rate is in the 95% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 25.0% of cases where such amendments are filed. This entry rate is in the 33% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
This examiner withdraws rejections or reopens prosecution in 0.0% of appeals filed. This is in the 0% percentile among all examiners. Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 100.0% are granted (fully or in part). This grant rate is in the 90% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.